Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450255 | 0.83 | HTR6 (0.45) | HTR6KMT2AMEN1HTTSLC9A1 | |
| SCHEMBL459216 | 0.81 | MEN1 (0.46) | HTR6KMT2AMEN1HTTSLC9A1 | |
| SCHEMBL12970761 | 0.77 | HTR6 (0.59) | HTR6KMT2AMEN1HTTSLC9A1 | |
| SCHEMBL1432113 | 0.76 | HTR6 (0.39) | HTR6KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL457624 | 0.76 | MAPT (0.39) | KMT2AMEN1HTTSLC9A1MAPT | |
| SCHEMBL110249 | 0.75 | HTR6 (0.43) | HTR6KMT2AMEN1SLC9A1MAPT | |
| SCHEMBL456826 | 0.73 | ALDH1A1 (0.44) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1432115 | 0.72 | HTR6 (0.36) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1431296 | 0.72 | HTR6 (0.39) | HTR6KMT2AMEN1HTTSLC9A1 | |
| SCHEMBL1252454 | 0.72 | HTR6 (0.40) | HTR6KMT2AMEN1HTTSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2280946-B1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-8765743-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| EP-2507231-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507223-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507226-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067366-A1 | INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| US-20110118246-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2300437-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2280959-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| EP-2280946-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147190-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | HTR6 1564/4885KMT2A 2534/4885MEN1 4734/4885 |
| US-20110118246-A1 | Novel Compounds | PIK3CA, PIK3C2B, PIK3CD | HTR6 4428/4885KMT2A 3508/4885MEN1 1232/4885 |
| US-20110112070-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | CDK3, CDK13, MAP3K13 | HTR6 3938/4885KMT2A 1786/4885MEN1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.